LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

This study tests whether combining a special immune cell therapy called LV20.19 CAR T-cells with a targeted drug called pirtobrutinib can better treat relapsed or treatment-resistant B-cell lymphoma — a type of blood cancer — compared to either treatment alone. **You may be eligible if...** - You are between 18 and 80 years old - You have relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), such as follicular lymphoma or diffuse large B-cell lymphoma - Your cancer has not responded to or has come back after previous treatments **You may NOT be eligible if...** - You are under 18 or over 80 years old - You do not have a B-cell NHL diagnosis - Your lymphoma has not relapsed or is not considered refractory Talk to your doctor to see if this trial is right for you.